Figure 2 | Scientific Reports

Figure 2

From: Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer

Figure 2

Large-scale analysis of the miR-107 plasma level in PCa patients and healthy volunteers. (a) We observed that the plasma level of miR-107 was significantly lower in PCa patients than in healthy volunteers (P < 0.0001). A waterfall plot also demonstrated a similar result (P < 0.0001). (b) Receiver-operating characteristic (ROC) curves and area under the ROC curve (AUC) values were used to assess the feasibility of using plasma miRNA levels as a diagnostic tool for detecting PCa. We calculated the AUC value to be 0.851. The optimal relative expression cut-off point was found to be 20.5 using the miR-107/cel-miR-39 ratio, with a sensitivity of 82.0%, a specificity of 68.8%, and an accuracy of 82.0%.

Back to article page